- Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012 - Conditions: Sarcoma; Solid Tumors; Pulmonary Metastases; Lung Metastases; Osteosarcomas; Ewing Sarcoma
Interventions: Drug: Aerosol IL-2; Procedure: Symptom Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Shannon Wilkes Foundation
Not yet recruiting - verified May 2012 - Conditions: Cervical Cancer; Oropharyngeal Cancer; Vaginal Cancer; Anal Cancer; Penile Cancer
Interventions: Drug: Fluderabine; Drug: Cycolphosphamide; Biological: Young TIL; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Metastatic Cancer; Melanoma
Interventions: Drug: Vemurafenib; Drug: Young TIL; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Metastatic Cancer; Pancreatic Cancer; Mesothelioma
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Hydroxychloroquine; Drug: IL-2
Sponsors: University of Pittsburgh; University of Pittsburgh; Prometheus Laboratories
Recruiting - verified March 2012 - Conditions: Mestatic Melanoma; Skin Cancer
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Drug: Aldesleukin; Drug: MART-1 Reactive CD8+ PBL
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Adult Liposarcoma; Adult Synovial Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: recombinant interferon gamma; Biological: aldesleukin; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: biopsy; Biological: NY-ESO-1-specific T lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Malignant Glioma; Glioblastoma; Brain Cancer
Interventions: Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Melanoma
Interventions: Drug: Ipilimumab; Drug: Temozolomide; Drug: Cisplatin; Drug: Interferon Alfa-2b; Drug: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified February 2012 - Conditions: Metastatic Renal Cell Carcinoma; Metastatic Melanoma
Intervention:
Sponsors: Prometheus Laboratories; Prometheus Laboratories
Recruiting - verified September 2011 - Condition: Neuroblastoma
Interventions: Drug: Zoledronic Acid; Biological: Aldesleukin
Sponsors: University of Alabama at Birmingham; Joseph Pressey, MD
Recruiting - verified December 2011 - Conditions: Leukemia; Chronic Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Busulfan; Procedure: NK cell infusion:; Drug: Interleukin-2; Drug: Anti-Thymocyte Globulin; Procedure: Allogeneic related Stem Cell Transplant; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Aldesleukin; Biological: Tumor Infiltrating Lymphocytes
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Drug: cyclophosphamide; Biological: aldesleukin; Biological: autologous tumor cell vaccine; Other: laboratory biomarker analysis; Other: immunologic technique; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Biological: therapeutic autologous lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Young Tumor Infiltrating Lymphocytes; Procedure: 1200 Gy Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Melanoma (Skin)
Interventions: Biological: aflibercept; Biological: aldesleukin
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Metastatic Cancer; Metastatic Melanoma; Renal Cancer
Interventions: Genetic: Anti-VEGFR2 CAR CD8 plus PBL; Drug: Cyclophosphamide; Drug: Aldesleukin; Drug: Fludarabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Metastatic Colorectal Cancer; Metastatic Gastric Cancer; Metastatic Pancreatic Cancer; Metastatic Hepatocellular Carcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: CD8+ young TIL; Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Ependymoblastoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Grade III Meningioma; Meningeal Hemangiopericytoma; Mixed Glioma; Pineal Gland Astrocytoma; Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Other: laboratory biomarker analysis; Procedure: positron emission tomography
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011 - Condition: Renal Cell Carcinoma
Intervention: Drug: Aldesleukin
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic MelanomaCondition: Metastatic Melanoma
Interventions: Procedure: Surgery; Drug: Administration of Lymphodepletion; Other: Adoptive Cell Transfer; Drug: High Dose IL-2
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified January 2012 - Condition: High Risk Non-Hodgkin's Lymphoma
Interventions: Biological: Rituximab; Biological: Interleukin-2
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012 - Conditions: Lymphoma; B-cell Lymphoma
Interventions: Procedure: Leukapheresis; Procedure: Stem Cell Transplant; Procedure: CD19-specific T Cell Infusion; Drug: IL-2; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Large Cell Lymphoma
Interventions: Genetic: Anti-CD19-CAR Transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Renal Cancer; Kidney Cancer
Interventions: Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn; Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Drug: cyclophosphamide; Procedure: biopsy; Biological: aldesleukin; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Other: immunoenzyme technique; Biological: therapeutic allogeneic cytotoxic T lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Biological: allogeneic large multivalent immunogen breast cancer vaccine; Biological: aldesleukin
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Conditions: Wiskott-Aldrich Syndrome (WAS); X-linked Thrombocytopenia
Intervention: Drug: Interleukin-2
Sponsors: Children's Hospital of Philadelphia; Jordan Orange
Recruiting - verified January 2012 - Conditions: Metastatic Melanoma; Metastatic Renal Cell Cancer; Metastatic Cancer
Interventions: Biological: therapeutic autologous lymphocytes; Biological: aldesleukin; Drug: cyclophosphaide; Drug: fludarabine phosphate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Lung Cancer
Interventions: Biological: EGFRBi-armed autologous activated T cells; Biological: aldesleukin; Biological: sargramostim
Sponsors: Roger Williams Medical Center; Roger Williams Medical Center
Recruiting - verified January 2012 - Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Conditions: Leukemia; Lymphoma
Intervention: Drug: T cell Induction via IL-2 to reduce GVHD
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2012 - Conditions: Metastatic Melanoma; Renal Cell Cancer
Intervention: Biological: aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells; Biological: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Chiron Corporation
Recruiting - verified March 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Aldesleukin Clinical Trials |
